You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 5, February 6, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (5)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Drug Therapy, Other
 •Surgical Interventions
 •Cardiovascular/ Cardiothoracic Surgery
 •Cardiovascular Disease/ Myocardial Infarction
 •Cardiovascular Intervention
 •Revascularization
 •Alert me on articles by topic

Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome

P. Michael Ho, MD, PhD; Eric D. Peterson, MD, MPH; Li Wang, MS; David J. Magid, MD, MPH; Stephan D. Fihn, MD, MPH; Greg C. Larsen, MD; Robert A. Jesse, MD, PhD; John S. Rumsfeld, MD, PhD

JAMA. 2008;299(5):532-539.

Context  It is unknown whether patients are at increased short-term risk for adverse events following clopidogrel cessation.

Objective  To assess the rates of adverse events after stopping treatment with clopidogrel in a national sample of patients with acute coronary syndrome (ACS).

Design, Setting, and Patients  Retrospective cohort study of 3137 patients with ACS discharged from 127 Veterans Affairs hospitals between October 1, 2003, and March 31, 2005, with posthospital treatment with clopidogrel.

Main Outcome Measure  Rate of all-cause mortality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel.

Results  Mean (SD) follow-up after stopping treatment with clopidogrel was 196 (152) days for medically treated patients with ACS without stents (n = 1568) and 203 (148) days for patients with ACS treated with percutaneous coronary intervention (PCI) (n = 1569). Among medically treated patients, mean (SD) duration of clopidogrel treatment was 302 (151) days and death or AMI occurred in 17.1% (n = 268) of patients, with 60.8% (n = 163) of events occurring during 0 to 90 days, 21.3% (n = 57) during 91 to 180 days, and 9.7% (n = 26) during 181 to 270 days after stopping treatment with clopidogrel. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90-day interval after stopping treatment with clopidogrel was associated with a significantly higher risk of adverse events (incidence rate ratio [IRR], 1.98; 95% confidence interval [CI], 1.46-2.69 vs the interval of 91-180 days). Similarly, among PCI-treated patients with ACS, mean (SD) duration of clopidogrel treatment was 278 (169) days and death or AMI occurred in 7.9% (n = 124) of patients, with 58.9% (n = 73) of events occurring during 0 to 90 days, 23.4% (n = 29) during 91 to 180 days, and 6.5% (n = 8) during 181 to 270 days after stopping clopidogrel treatment. In multivariable analysis including adjustment for duration of clopidogrel treatment, the first 90-day interval after stopping clopidogrel treatment was associated with a significantly higher risk of adverse events (IRR, 1.82; 95% CI, 1.17-2.83).

Conclusions  We observed a clustering of adverse events in the initial 90 days after stopping clopidogrel among both medically treated and PCI-treated patients with ACS, supporting the possibility of a clopidogrel rebound effect. Additional studies are needed to confirm the clustering of events after stopping clopidogrel, including associations with cardiovascular mortality and reasons for stopping clopidogrel, as well as to determine the mechanism of this phenomenon, and to identify strategies to reduce early events after clopidogrel cessation.


Author Affiliations: Denver VA Medical Center, Denver, Colorado (Drs Ho and Rumsfeld); University of Colorado Health Sciences Center, Denver (Drs Ho, Magid, and Rumsfeld); Duke Clinical Research Institute, Durham, North Carolina (Dr Peterson); VA Puget Sound Health Care System, Seattle, Washington (Ms Wang and Dr Fihn); Institute for Health Research, Kaiser Permanente of Colorado, Aurora (Drs Ho, Magid, and Rumsfeld); Portland VA Medical Center, Portland, Oregon (Dr Larsen); Richmond VA Medical Center, Richmond, Virginia (Dr Jesse); and Virginia Commonwealth University Health System, Richmond (Dr Jesse).


RELATED LETTERS

Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Dae Hyun Kim
JAMA. 2008;299(20):2388-2389.
EXTRACT | FULL TEXT  

Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Sandeep K. Goyal and Sujeeth R. Punnam
JAMA. 2008;299(20):2389.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Progress Is Precarious
Head and Barash
Anesth. Analg. 2008;107:362-364.
FULL TEXT  

Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Kim
JAMA 2008;299:2388-2389.
FULL TEXT  

Adverse Events Associated With Stopping Clopidogrel After Acute Coronary Syndrome
Goyal and Punnam
JAMA 2008;299:2389-2389.
FULL TEXT  

All you need to read in the other general journals
BMJ 2008;336:354-355.
FULL TEXT  

Clopidogrel Rebound?
Journal Watch Cardiology 2008;2008:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.